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ABSTRACT
RNA-seq has become a popular technology for
studying genetic variation of pre-mRNA alternative
splicing. Commonly used RNA-seq aligners rely on
the consensus splice site dinucleotide motifs to
map reads across splice junctions. Consequently,
genomic variants that create novel splice site din-
ucleotides may produce splice junction RNA-seq
reads that cannot be mapped to the reference
genome. We developed and evaluated an approach
to identify ‘hidden’ splicing variations in personal
transcriptomes, by mapping personal RNA-seq data
to personal genomes. Computational analysis and
experimental validation indicate that this approach
identifies personal specific splice junctions at a low
false positive rate. Applying this approach to an RNA-
seq data set of 75 individuals, we identified 506 per-
sonal specific splice junctions, among which 437
were novel splice junctions not documented in cur-
rent human transcript annotations. 94 splice junc-
tions had splice site SNPs associated with GWAS
signals of human traits and diseases. These involve
genes whose splicing variations have been impli-
cated in diseases (such as OAS1), as well as novel as-
sociations between alternative splicing and diseases
(such as ICA1). Collectively, our work demonstrates
that the personal genome approach to RNA-seq read
alignment enables the discovery of a large but previ-
ously unknown catalog of splicing variations in hu-
man populations.
INTRODUCTION
Exons can be differentially included in the mature mRNA
products during splicing (1). This process, called alterna-
tive splicing (AS), is one of the predominant mechanisms
for generating distinct mRNA isoforms from a single gene.
It is estimated that over 90% of human multi-exon genes
are alternatively spliced (2,3). AS plays a crucial role in gene
regulation and abnormal variations in splicing can have sig-
nificant disease consequences (4). In fact, as high as 50% of
disease-causing mutations in specific disease genes may al-
ter splicing (5,6).
In recent years, numerous studies have identified single
nucleotide polymorphisms (SNPs) that are associated with
changes in nearby AS events, commonly referred to as splic-
ing quantitative trait loci (sQTLs) (7–10). Collectively, these
studies have established that natural genetic polymorphisms
in the human population may cause differences in exon us-
age patterns or splicing efficiencies among individuals. Such
natural variation of alternative splicing may in turn influ-
ence disease risk or severity or therapeutic response (11–13).
Thus, the discovery of sQTLs will reveal potential mecha-
nisms underlying human phenotypic diversity and suscep-
tibility to genetic disorders.
AS is regulated by a wide array of cis regulatory ele-
ments on the pre-mRNA as well as trans-acting factors that
interact with these cis elements (14). The most conserved
cis splicing signals within the pre-mRNA are the 5′ and 3′
splice sites, which define the boundary between exons and
introns. Approximately 99% of mammalian splice sites fol-
low the ‘GT-AG’ dinucleotide rule such that the first two
and last two nucleotides in the intron are GT and AG, re-
spectively.Of the remaining splice sites,≈0.9%are ‘GC-AG’
and ≈0.09% are ‘AT-AC’ (15). Genetic variants that dis-
rupt or create the highly conserved splice site dinucleotide
motifs can alter splicing patterns and produce alternative
mRNA and protein isoforms (16). Indeed, mutations that
affect splice site dinucleotides represent a large class of hu-
man disease mutations (17).
RNA sequencing (RNA-seq) has emerged as a powerful
method for discovering and quantifying AS events at the
whole-transcriptome scale. In a typical RNA-seq data anal-
ysis workflow, sequenced fragments of mRNA (i.e. reads)
are aligned to the reference genome sequence and/or exist-
ing transcript annotations, and reads corresponding to spe-
cific exons and splice junctions are identified and counted
to generate quantitative estimates of gene expression and
alternative splicing (18–21). A number of studies have used
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this strategy to identify associations between genetic poly-
morphisms and alternative splicing events in human pop-
ulations (22–28). However, the use of the reference genome
has important limitations for studying individual variations
of transcriptomes. For example, it is well known that when
mapping reads to the reference genome, exonic SNPs can
create a bias for mapping RNA-seq reads harboring the ref-
erence alleles over reads harboring the derived alleles, which
may skew the quantitation of allelic ratios in RNA-seq
data and confound downstream analyses of allele-specific
gene expression and RNA processing (29). Methods have
been developed to alleviate such biases in mapping personal
RNA-seq data (30–32). Another major limitation, which
is the main motivation for this work, is the identification
of splice junctions from personal RNA-seq reads aligned
to the reference genome. Many commonly used RNA-seq
aligners, including Tophat and SpliceMap (33,34), rely on
the canonical (e.g. GT-AG,GC-AG,AT-AC) splice site din-
ucleotide motifs and do not align reads to non-canonical
splice junctions. Other aligners, such as STAR and HISAT
(35,36), apply a severe score penalty to non-canonical splice
junction alignments. As a result, if a genetic polymorphism
creates a novel splice site dinucleotide motif in an individ-
ual, RNA-seq reads that originate from the polymorphic
splice site in the personal genome will likely be unmappable
to the human reference genome due to the lack of the canon-
ical splice site dinucleotide motif in the reference genome
sequence (Figure 1A). This would result in ‘hidden’ splicing
variations that are undetected by standard RNA-seq align-
ment procedures.
In this work, we explored whether a personal genome
approach to RNA-seq alignment could detect such hid-
den splicing variations. In a collection of RNA-seq data of
75 European individuals from the 1000 Genomes Project,
we identified 506 ‘hidden’ personal splice junctions with
polymorphic splice site dinucleotides that were supported
by RNA-seq reads unmappable to the human reference
genome. 437 of these splice junctions were novel, i.e. not in
current human transcript annotations, and 94 were linked
to genome-wide association study (GWAS) signals. Our
data demonstrate that by mapping personal RNA-seq data
to personal genomes, we can uncover numerous novel splic-
ing variations in the human population, including those po-
tentially underlyingGWAS signals of complex human traits
and diseases. We refer to our pipeline RNA-seq Personal
Genome-alignment Analyzer (rPGA). The rPGA source
code and user documents are freely available for download
at https://github.com/Xinglab/rPGA.
MATERIALS AND METHODS
RNA-seq data sets
RNA-seq data for NA12891 were obtained from the NCBI
Sequence Read Archive (SRR074943) (24). RNA-seq data
for 75 European individuals were obtained from the Geu-
vadis RNA Sequencing Project (Supplementary Table S1;
EBI ArrayExpress: E-GEUV-1) (23). All RNA-seq data
were generated on lymphoblastoid cell lines (LCLs). Geno-
type data for these individuals were taken from the 1000
Genomes Browser (37). The genotype data were filtered to
only include phased SNPs.
RNA-seq read alignment
For each individual, the paired-end RNA-seq reads were
aligned to hg19 and two haplotype versions (hap1 and
hap2) of the personal genome using STAR (version 2.4.0f1)
(35), generating three separate sets of alignment data. The
maximum number of mismatches within reads was set to
0, the maximum number of multihits was set to 20 and
the maximum intron size was set to 300 000. The mini-
mum overhang length for splice junctions was set to 12
for GT/AG, GC/AG and AT/AC splice site dinucleotide
motifs. Spliced alignments containing non-canonical splice
junctions were not permitted. Truncated reads and reads
with a truncated pair were considered unmapped.
Identification of personal specific splice junctions
Hap1 specific junctions were splice junctions reported solely
in the hap1 alignment data. Similarly, hap2 specific junc-
tions were splice junctions reported solely in the hap2 align-
ment data and hap1hap2 specific junctions were splice junc-
tions found in both the hap1 and hap2 alignment data but
not in the hg19 alignment data. Personal specific splice
junctions were defined to be the union of hap1, hap2 and
hap1hap2 specific splice junctions. Likewise, splice junc-
tions reported solely in the hg19 alignment data were called
hg19 specific junctions, which can be used to assess the false
positive rate of our procedure. Distinct reads were ones that
had distinct starting alignment positions. We required per-
sonal specific splice junctions to be supported by≥2 distinct
reads for all further analyses.
Splice site usage frequency
To compare the relative splicing activities at a personal spe-
cific splice site to nearby alternative splice sites, we calcu-
lated the splice site usage frequency using RNA-seq data.
Note that frequencies were calculated only in the genome
where the splice junction was identified. For example, a per-
sonal specific splice junction identified in one haplotype was
only compared to all other junctions also found in that hap-
lotype.
To calculate the relative usage frequency of personal
splice junctions, we considered all Ensembl annotated splice
junctions with overlapping genomic coordinates with our
personal splice junction of interest. PSJ is the number of
reads that span the personal specific splice junction andOSJ
is the total number of reads that span all overlapping En-
sembl annotated junctions. The relative usage frequency of
the personal splice junction is PSJ/(PSJ + OSJ). We also
performed this calculation for a subset of personal specific
splice junctions that overlapped with only one other splice
junction via alternative 5′ or 3′ splice site patterns. The num-
ber of reads supporting a splice junction was counted as the
number of distinct splice junction spanning reads, i.e. reads
with distinct genomic starting alignment positions.
Association with GWAS signals
We obtained 207 889 GWAS SNPs with P-value < 10−3
from the GWASdb2 v4 catalog (38). We used PLINK
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Figure 1. Identifying hidden splice junctions by aligning personal RNA-seq reads to personal genomes. (A) RNA-seq splice junction reads originating
from SNPs creating personal splice site dinucleotide motifs (shown in red) do not align to the reference genome due to non-canonical splice site motifs in
the reference genome. The RNA-seq splice junction reads do, however, align to the personal genome. (B) Flowchart of the rPGA pipeline.
v1.08p to calculate linkage disequilibrium (LD) correla-
tions between splice site SNPs at personal specific splice
junctions and all GWAS SNPs (39). The LD map was cre-
ated using a CEU population and PLINK v1.07. We then
identified splice site SNPs in high LD (r2 > 0.8) withGWAS
SNPs.
Linkage disequilibrium plot
Linkage disequilibrium (LD) plot for SNP rs6948664 was
generated using Haploview v4.2 (40). CEU LD data were
obtained from the HapMap Project Genome Browser ver-
sion E, using data release #28 (Phase II+III).
Splice site score
Splice site (SS) scores (5′ or 3′ splice sites) were calculated
using the MaxEntScan maximum entropy model (41). In
cases where the personal SNP also affected the reference
splice site, reference splice site sequences were changed ac-
cordingly to reflect the personal SNP. We defined (SS
score) = personal splice site score––reference splice site
score, where (SS score) > 0 corresponds to a personal
splice site that is stronger than the alternative reference
splice site.
Experimental validation of personal specific splice junctions
HapMap LCLs were purchased from the Coriell Institute
for Medical Research (Camden, NJ, USA). We prepared
HapMap LCLs’ cDNAs as described before (42). To vali-
date personal specific splice junctions, we designed a pair of
polymerase chain reaction (PCR) primers targeting flank-
ing constitutive exons of the novel splice junction. Regular
PCRwas carried out for 40 cycles. Final PCRproducts were
purified by gel extraction and then confirmed by Sanger se-
quencing (Laragen, Inc, CA, USA). Primer sequences and
HapMap individuals selected for PCR validation are shown
in Supplementary Table S2.
RESULTS
A computational pipeline to identify personal splice junctions
by mapping personal RNA-seq data to personal genomes
We developed a computational pipeline rPGA (Figure 1B)
to discover hidden splice junctions by mapping personal
RNA-seq data to the matching personal genome sequence.
We applied this pipeline to analyze RNA-seq data from
individuals with whole-genome genotype data in the 1000
Genomes project. Briefly, for each individual we modi-
fied the human reference genome (hg19) according to its
genotype, resulting in two versions of personal genome se-
quences per individual (one for each haplotype), which we
referred to as haplotype 1 (hap1) and haplotype 2 (hap2)
in this manuscript. Next, an individual’s RNA-seq reads
were aligned to the human reference genome (hg19) and
each of the two corresponding personal genomes (hap1 and
hap2) using the RNA-seq alignment software STAR (35),
resulting in three separate sets of alignment data per indi-
vidual. We should note that STAR truncates a read once
it reaches the maximum number of allowed mismatches or
has too low of an alignment score (35). We considered such
truncated reads as well as reads that did not align at all
unmappable reads. We then remapped reads that were un-
mappable to hg19 to personal genomes (hap1 and hap2)
to identify personal specific splice junctions (Figure 1). To
constrain our analysis to the effect of splice site SNPs, we
filtered out personal specific splice junctions with no SNP
at the splice site dinucleotide motifs. 99.2% of filtered per-
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sonal specific splice junctions were supported by reads that
could have been aligned to the same location in the hg19
reference genome, but contained SNP(s) elsewhere along
the reads that made them unmappable to hg19 due to the
number of mismatches exceeding the aligner’s threshold.
To assess the rate of false positives from this pipeline, we
reversed the alignment procedure by re-aligning reads un-
mappable to personal genomes (hap1 and hap2) to hg19
to identify hg19-specific splice junctions. We consider such
hg19-specific splice junctions false positives, because their
supporting splice junction reads were generated from the
personal genome sequence of the individual.
As a proof-of-concept analysis using this pipeline, we ini-
tially performed personal genome RNA-seq alignment us-
ing RNA-seq data of a male Caucasian (NA12891) (24).
We identified 33 personal specific splice junctions, includ-
ing 24 novel splice junctions not documented in current hu-
man transcript annotations (Ensembl version #75). The re-
verse mapping procedure (see above) identified only 3 hg19-
specific splice junctions, suggesting that our pipeline has
low false positives. We also checked whether our pipeline
could identify known alternative splicing variations arising
from personal specific splice junctions. Indeed, we success-
fully captured a known personal specific 3′ splice site of in-
tron 20 in NPHP4 associated with SNP rs1287637 (T > A
on the RNA sense strand which created an ‘AG’ 3′ splice
site). NPHP4 is involved in renal function and its muta-
tions are known to cause juvenile end stage renal disease
(43). The personal splice junction is supported by 5 distinct
reads, though it is unlikely to be identified through tradi-
tional reference genome based RNA-seq mapping because
the supporting reads are unmappable to hg19 due to the
lack of canonical splice site dinucleotides in the reference
genome. Interestingly, the T allele in the reference genome
causes activation of two downstream 3′ splice sites and is as-
sociated with alternative transcript isoforms with 6 nt and
42 nt deletions of exon 21. Individuals carrying the ‘T’ allele
of SNP rs1287637 (i.e. A/T or T/T genotype) have reduced
renal functionmanifested as decreased glomerular filtration
rate (43). This example shows that our strategy can identify
personal specific splice junctions that would otherwise be
missed when mapping RNA-seq reads to the reference hu-
man genome.
Comprehensive identification of personal specific splice junc-
tions in 75 European individuals
Next, we expanded our analysis to RNA-seq data of 75
European individuals. These data were obtained from the
Geuvadis RNA sequencing project on 1000 Genomes sam-
ples (23) (see Materials and Methods). We identified a to-
tal of 506 distinct personal specific splice junctions among
the 75 individuals (Figure 2A and Supplementary Table S3),
with at least two distinct supporting RNA-seq reads in at
least one individual. The reverse alignment procedure iden-
tified only 27 hg19-specific splice junctions. In fact, at the
same threshold of supporting evidence, the number of hg19-
specific splice junctions was always at most a few percent of
the number of personal specific splice junctions (see Supple-
mentary Figure S1), suggesting that the false positive rate of
our pipeline was consistently low even for splice junctions
identified in only a single individual. We also compared
our results to the Ensembl transcript annotations (version
#75) (44) to classify personal specific splice junctions as
either known or novel. The 506 splice junctions included
69 known and 437 novel splice junctions (Figure 2B). Our
list of 69 known personal specific splice junctions includes
events with documented disease relevance. For example, a
known personal specific splice junction in IRF5 was iden-
tified in 25 individuals. Splice site SNP rs2004640 (G > T
on the RNA sense strand) creates an alternative ‘GT’ 5′
splice site to enable the splicing of exon 1B as an alterna-
tive first exon (45). Interestingly, IRF5 has four alternative
first exons, all of which are in the 5′-UTR (46). Exon 1B
is the only alternative first exon with a p53-binding site in
the associated promoter region (47). Furthermore, the T al-
lele of rs2004640 has 2.7-fold higher IRF5mRNA level (46).
Overexpression of IRF5 is associated with susceptibility of
autoimmune diseases, including systemic lupus erythema-
tous, rheumatoid arthritis and multiple sclerosis (48,49). A
second example is a known splice junction in CPNE1 iden-
tified in 9 individuals. An exonic SNP rs2425068 (A > G)
immediately downstream of the canonical 3′ splice site cre-
ates a pair of tandem NAGNAG 3′ splice sites (CAGCAA
> CAGCAG) (50). Use of the downstream 3′ splice site re-
sults in one amino acid 413Q deletion in the VWFA (Von
Willebrand Factor Type A) domain. This SNP is associated
with plasma protein C levels and potentially venous throm-
boembolism (51).
We next asked whether these ‘hidden’ personal splice
junctions could be expressed at a high enough level to be
considered more than just baseline splicing noise. For this
analysis, we calculated the relative usage frequency of the
identified personal splice junctions usingRNA-seq data (see
Materials andMethods). As expected, personal splice junc-
tions had a wide range of usage frequencies. 460, 311 and
193 of the 506 personal splice junctions had an average us-
age frequency no less than 5%, 15% and 50%, respectively,
when detected. For example, SNP rs2004640 (G > T) in
IRF5 as mentioned above had average personal splice junc-
tion usage frequency of ≈11% in 25 individuals, while SNP
rs2425068 (A > G) in CPNE1 had average personal splice
junction usage frequency of ≈65% in 9 individuals. We also
calculated the detection frequency of personal splice junc-
tions across individuals, as the percentage of individuals
with a given personal splice junction detected among all in-
dividuals carrying the splice site SNP. We found that 323,
218 and 108 personal splice junctions had a detection fre-
quency no less than 5%, 15% and 50%, respectively, among
individuals carrying the splice site SNPs. These results in-
dicate that personal specific splice junctions arising from
splice site polymorphisms can be used in a significant por-
tion of the final transcript products within the population.
We performed an in-depth analysis to assess how the us-
age frequency of personal specific splice junctions was cor-
related with the strength of their associated splice sites. To
remove potential confounding factors and obtain meaning-
ful estimates of splice junction usage frequencies, we im-
posed several additional requirements: first, the personal
specific splice junction must form alternative 5′ or 3′ splice
sites with exactly one other reference splice junction ex-
pressed in the personal transcriptome; second, the personal
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Figure 2. Number of personal specific splice junctions supported by different numbers of RNA-seq reads and individuals. Heatmap of (A) the total
number of personal specific splice junctions, and (B) the total number of novel personal specific splice junction identified across 75 CEU individuals.
Columns represent an increasing requirement for the minimum number of supporting splice junction reads. Rows represent an increasing requirement for
the minimum number of supporting individuals.
and reference splice junctions must have a minimum com-
bined read count of 10 distinct RNA-seq reads to ensure
a high enough coverage for estimating splice junction us-
age frequencies; and third, individuals must be homozy-
gous for the splice site SNP because relative splice junc-
tion frequency in the RNA-seq data is dependent on the
genotype of the individual. We identified a total of 149 in-
stances of personal specific splice junctions that met these
criteria. Among them, 77 had weaker splice sites compared
to the reference splice sites, and 72 had stronger splice sites
compared to the reference splice sites. We found that per-
sonal splice junctions with stronger splice sites had signif-
icantly higher usage frequencies than those with weaker
splice sites (mean frequency 36.2% versus 19.7%; P = 5.5
× 10−4, Wilcoxon test) (Supplementary Figure S2).
Experimental validation of personal specific splice junctions
Weused PCR followed by Sanger sequencing to perform ex-
perimental validation of novel personal specific splice junc-
tions. PCR analyses were carried out in lymphoblastoid cell
lines (LCLs) carrying the personal specific splice junctions
of interest. To facilitate PCR primer design and analysis,
we randomly selected eight novel personal specific splice
junctions which had alternative 5′ or 3′ splice site patterns
with at least one other annotated splice site and a usage fre-
quency of at least 10% in the corresponding individuals. A
pair of PCR primers targeting flanking constitutive exons
was designed for each novel personal specific splice junc-
tion. Putative PCR amplicons were further confirmed by
Sanger sequencing. All eight novel splice junctions were val-
idated (Table 1). We validated novel personal specific splice
junctions present in as few as 1 individual and as many as
69 individuals.
One example of validated splice junctions is a personal
splice junction of exon 6 of OAS1, observed in RNA-seq
data of 69 individuals. OAS1 encodes 2′-5′-oligoadenylate
synthetase and is involved in viral and endogenous RNA
degradation to inhibit viral replication (52). Splice site SNP
rs10774671 (G > A) creates a cryptic 3′ splice site that is
shifted 1 nt downstream from the canonical 3′ splice site in
the reference genome. Simultaneously, rs10774671 corrupts
the reference 3′ splice site (AG > AA) as shown in Figure
3A. Usage of the personal splice junction is predicted to
produce a protein isoform (i.e. p52) with reduced enzyme
activity and can thus affect immune response to viral infec-
tion (53).
A second example is a novel personal specific splice junc-
tion in exon 8 of DHRS12 that was identified in one indi-
vidual (Figure 3B). DHRS12 codes for an enzyme in the
short-chain dehydrogenases/reductases (SDR) family. Al-
though DHRS12 itself is not a well-characterized gene, it is
known that SDRs in general are responsible for metaboliz-
ing substances in the body including hormones and xeno-
biotics (54–56). Mutations in these genes have been associ-
ated with a variety of metabolic disorders (57). Splice site
SNP rs2296028 (C > G on the RNA sense strand) creates
a stronger, novel 3′ splice site (splice site score = 9.61 by
MAXENT (41)) 5 nt upstream from the reference 3′ splice
site (score = 4.11) (Figure 3B). Moreover, the G allele of
SNP rs2296028 decreases the reference 3′ splice site score
from 4.11 to 0.25. RNA-seq data as well as our PCR and
sequencing data indicate that this much stronger novel 3′
splice site is used in one individual heterozygous for the
splice site SNP.
We should note that these eight validated splice junc-
tions were randomly selected from our identified novel per-
sonal specific splice junctions, rather than being cherryp-
icked from the most frequently expressed and identified
novel splice junctions. Our independent experimental val-
idation confirmed the existence of hidden personal splicing
variations that would otherwise be overlooked by mapping
personal RNA-seq reads to the reference genome.
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Table 1. Experimental validation of novel personal specific splice junctions
Gene symbol
Genomic
coordinates (hg19)
Average relative
usage frequency
Frequency
standard deviation
# Individuals
supported
GWAS
disease/trait Validated novel
ANXA6 chr5:150483256–150484805 0.48 0 1 Yes Yes
ARSG chr17:66352945–66364691 0.82 0.18 15 Yes Yes
ASMTL chrX:1540735–1544272 0.10 0 1 Yes Yes
DHRS12 chr13:52345636–52345956 0.23 0 1 Coronary Artery
Disease (72)
Yes Yes
GRAMD1A chr19:35505291–35506730 0.65 0.08 43 Yes Yes
NPNT chr4:106816880–106819054 0.65 0.28 9 Yes Yes
OAS1 chr12:113355505–113357194 0.21 0.07 69 Multiple complex
diseases (73)
Yes Yes
U2AF1L4 chr19:36233704–36234652 0.28 0.09 6 Yes Yes
Figure 3. Experimental validation and sequencing chromatograms of personal specific splice junctions inOAS1 andDHRS12. (A) SNP rs10774671 creates
a personal 3′ splice site of OAS1. The reference 3′ splice site produces an intact protein isoform p46. The SNP rs10774671 (G to A) abolishes the reference
3′ splice site, resulting in the usage of a personal 3′ splice site and an internal cryptic 3′ splice site corresponding to alternative protein isoforms p52 and
p48 with reduced enzyme activity. (B) SNP rs2296028 creates a personal 3′ splice site 5 nt upstream of the reference 3′ splice site of DHRS12 exon 8. This
SNP also decreases the score of the reference 3′ splice site from 4.11 to 0.25. 3′ SS: 3′ splice site.
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Personal specific splice junctions are linked to GWAS signals
of complex traits and diseases
Finally, we investigated whether our discovered personal
specific splice junctions were associated with GWAS sig-
nals of complex traits and diseases. GWAS studies have
identified an abundance of associations between genomic
variants and phenotypes. Interpreting the growing catalog
of GWAS signals is a powerful application for elucidating
human transcriptome variation (23). However, more often
than not, GWAS signals merely serve as markers for phe-
notype association and reveal little regarding the underly-
ing causal genomic variants as well as the molecular mech-
anisms for phenotype variability or disease pathogenesis
(58). Although initial analyses of GWAS signals focused
on those in protein coding regions, recent evidence suggests
that many functional variants lie in non-coding regions
and affect phenotypes through regulatorymechanisms (59).
As alternative splicing plays a powerful role in transcrip-
tome variation and phenotype diversity (13), personal spe-
cific splice junctions arising from splice site SNPs are likely
candidates for functional causal variants associated with
GWAS signals. To investigate this, we sought to identify all
personal splice junction associated splice site SNPs in high
(r2 > 0.8) LD with GWAS signals listed in GWASdb2 v4
(see Materials and Methods) (38). GWASdb integrates a
number of well-established collections of GWAS SNPs, in-
cluding the commonly used NHGRI GWAS catalog (60).
We identified 9 known and 85 novel personal specific splice
junctions with splice site SNPs linked to GWAS signals
(Supplementary Table S4 and Table 2). The list includes
our experimentally validated splice junctions in OAS1 and
DHRS12 (described above), as well as other personal splice
junction associated SNPs with potential medical signifi-
cance.
A highly intriguing example is a personal specific splice
junction in ICA1. ICA1 encodes autoantigen ICA69, which
is involved in vehicular transport of insulin secretory gran-
ule proteins and is known to play an important role in au-
toimmune diseases, including type 1 diabetes, rheumatoid
arthritis and Sjogren’s syndrome (61–64). SNP rs6948664
(C > T) activates a novel 5′ splice site (GC > GT, 5′ splice
site score = 8.4) in intron 12 of ICA1. Our RNA-seq align-
ment indicates that this novel 5′ splice site is paired with
the downstream 3′ splice site of exon 13. However, in the
RNA-seq data we did not find any splice junction reads
from exon 12 or other upstream exons into the potential
novel exon within intron 12, raising the possibility that this
novel personal specific splice junction may be associated
with a novel alternative first exon within intron 12. To test
this hypothesis, we designed a pair of PCRprimers targeting
exon 12 and exon 13 of ICA1, and a separate pair of PCR
primers targeting the potential novel exon in intron 12 and
exon 13. As expected, the novel personal specific splice junc-
tion was only observed in individuals carrying the T allele
of rs6948664 (Figure 4). Moreover, the primer pair target-
ing the two flanking exons (exon 12 and 13) failed to am-
plify any PCR amplicon that contained the potential novel
exon in intron 12, suggesting that the novel personal specific
splice junction is not paired with an upstream splice junc-
tion that creates a novel internal exon of ICA1. Thus, we
conclude that rs6948664 activates a novel alternative first
exon in ICA1. Of note, the use of this novel alternative first
exon is expected to produce a much shorter mRNA isoform
(≈1100nt), compared to the full-length mRNA transcript
(2473 nt, NM 001136020), and the longest putative open
reading frame of the novel transcript is only 75aa. The pre-
dicted 75aa protein isoform has the same reading phase as
the canonical mRNA isoform but loses the AH domain,
which has been shown to dimerize and bind to Arf and
Rho family GTPases (65,66). Arf and Rho GTPases are re-
quired for regulation of many cellular processes including
cell motility and Golgi function (65). The novel personal
specific splice junction was identified in 23 individuals, with
an average usage frequency of 59%. Additionally, rs6948664
is in complete LD (r2 = 1) with GWAS signal rs4725072,
which has been identified as significantly associated with
systemic lupus erythematous (SLE) and systemic sclerosis
(38,67). However, no underlying causal variants were iden-
tified for SLE or systemic sclerosis in the original GWAS
study. Interestingly, individuals showing RNA-seq evidence
for the novel personal specific splice junction have signifi-
cantly higher ICA1 gene expression levels in LCL cells com-
pared to those without (P= 7× 10−3, Wilcoxon test). It has
been found that overexpression of ICA1 in insulinoma INS-
1 cells impairs secretory granule protein transport (61). Col-
lectively, our data suggest that rs6948664 is a likely causal
variant for SLE or systemic sclerosis by significantly affect-
ing ICA1’s expression level and/or protein output. We note
that recent work has described the roles of first exon and 5′
splice site in transcriptional regulation (68–70), which could
underlie our observed association between this alternative
first exon and ICA1 gene expression level. However, we can-
not rule out the possibility that this observation could be
due to the simple fact that it is more likely to detect such an
alternative mRNA isoform by RNA-seq when the overall
gene expression level is high. Further studies are needed to
assess the causal impact of this novel alternative first exon
on ICA1 gene transcription and function.
Of all GWAS-associated personal splice junctions, 63
formed alternative 5′ or 3′ splice sites with reference splice
junctions. 40 of these 63 GWAS-associated personal splice
junctions (63.5%) were potentially frame-shifting because
the distance between the personal and reference splice sites
was not an exact multiple of three nucleotides. The percent-
age was similar in non-GWAS-associated personal splice
junctions.
DISCUSSION
Dissecting the molecular mechanisms of transcriptome
variation in human populations is critical for understand-
ing the biology of complex traits and diseases. Alterna-
tive splicing is a major contributor to transcriptome vari-
ation and phenotypic diversity among human individuals
(9,10,13). Thus, identifying splicing variations in human
populations will shed light on the genetic basis of diseases.
A number of recent studies have used RNA-seq to charac-
terize genetic variation of alternative splicing in human cell
lines and tissues (22–28). These studies typically generate
quantitative estimates of alternative splicing using RNA-
seq reads aligned to a single reference genome. However, as
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Table 2. Selected list of personal specific splice junction SNPs linked to GWAS signals
Gene symbol Genomic coordinates (hg19) Novel Splice site SNP
Linked GWAS
SNP(s)
GWAS gene
symbol GWAS disease/trait Reference
AHRR chr5:428122–430060 Yes rs72717415 rs12188164 AHRR Cystic fibrosis severity (74)
ALG8 chr11:77838483–77850518 Yes rs10793289 rs10899440 ALG8 Endometriosis (75)
ATP5A1 chr18:43671818–43673144 Yes rs8083998 rs13381709,
rs7244921,
rs8089150
ATP5A1 HIV-1 disease progression (76)
DHRS12 chr13:52345636–52345956 Yes rs2296028 rs2296028 DHRS12 Coronary artery disease (72)
ICA1 chr7:8167773–8168380 Yes rs6948664 rs4725072 ICA1 Systemic lupus erythematosus and
Systemic sclerosis
(67)
NBR2 chr17:41290940–41291953 Yes rs11657835 rs11655505 BRCA1 Breast Neoplasms (77)
NDUFAF6 chr8:95988208–95993082 Yes rs6983948 rs16893776 Blood pressure (78)
OAS1 chr12:113355506–113357194 Yes rs10774671 rs2660 OAS1 Multiple complex diseases (73)
PPP1R3B chr8:8999187–9008072 Yes rs330924 rs330911 PPP11R3B Alzheimer`s disease (late onset) (79)
STYXL1 chr7:75630274–75633075 Yes rs8565 rs6978677 STYXL1 Lymphocyte counts (80)
Figure 4. Apersonal specific splice junction of ICA1 is linked toGWAS signals of diseases. (A)The schematic gene structure and sequencing chromatogram
of the novel personal specific splice junction in ICA1. SNP rs6948664 creates a novel personal 5′ splice site in intron 12 of ICA1, resulting in a novel
alternative first exon of ICA1. (B) Linkage disequilibrium (LD) plot of the CEU population indicates that the personal specific splice junction SNP
rs6948664 is in perfect LD with the GWAS SNP of systemic lupus erythematous and sclerosis rs4725072 (r2 = 1).
we demonstrated in this work, important splicing variations
may be missed by mapping personal RNA-seq reads to the
reference genome.
In this study we implemented a computational pipeline
rPGA (RNA-seq Personal Genome-alignment Analyzer;
https://github.com/Xinglab/rPGA) to identify splicing vari-
ations in individual transcriptomes, by mapping personal
RNA-seq reads to personal genomes. The importance of
using personal genome information has been discussed pre-
viously for RNA-seq studies, mostly for the purpose of re-
ducing allelic bias in mapping personal RNA-seq reads to
the reference genome (30–32). Here we investigated a dis-
tinct issue in RNA-seq alignment, namely the identification
of novel, personal specific splice junctions from personal
RNA-seq data. Because commonly used RNA-seq aligners
all rely on the consensus splice site dinucleotide motifs to
map reads across splice junctions, if a genetic polymorphism
creates a novel splice site dinucleotide motif, the result-
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ing splice junction reads utilizing this novel splice site will
likely be unmappable to the reference genome by a standard
RNA-seq aligner. Indeed, using a personal genome align-
ment approach, we identified many novel personal specific
splice junctions at a low false positive rate (Figure 2).More-
over, eight novel splice junctions selected for experimental
testingwere all validated byRT-PCRand sequencing. Thus,
our results indicate that we could uncover ‘hidden’ splicing
variations in individual transcriptomes by aligning personal
RNA-seq reads to personal genomes.We should clarify that
not all personal specific splice junctions are due to SNPs at
the splice site dinucleotide motifs, because other exonic or
intronic SNPs can also affect splicing. However, such differ-
ential splicing events could readily be detected by conven-
tional RNA-seq alignment procedures and sQTL detection
algorithms (26,71) and are not the focus of this work.
We identified 506 personal specific splice junctions in an
RNA-seq data set of 75European individuals, amongwhich
437 were novel splice junctions not documented in current
human transcript annotations (Ensembl version #75). 94
splice junctions had splice site SNPs associated with GWAS
signals of human traits and diseases. These involve genes
whose splicing variations have been implicated in diseases
(such asOAS1, Figure 3A), as well as novel associations be-
tween alternative splicing and disease (such as ICA1, Figure
4). To put these numbers in a proper context, as a compari-
son our previous analysis of alternative splicing in 41 Eu-
ropean individuals identified 140 splicing QTLs from the
RNA-seq data, including 10 linked to GWAS SNPs (26).
Thus, this personal genome approach to RNA-seq read
alignment allows us to tap into a large but previously un-
known catalog of splicing variations in human populations,
and should be recommended as a routine step for secondary
analyses of RNA-seq data with matching genome informa-
tion. Given that parallel sequencing of DNA and RNA has
become a popular strategy for genomic studies of diseases,
this approach may also be useful for discovering splicing
variations in diseased tissues with RNA-seq data matched
with exome sequencing or genome sequencing data. For ex-
ample, this approachmay help identify novel cancer-specific
splicing variations arising from somatic mutations that cre-
ate splice site dinucleotide motifs in cancer genomes. It is
also possible to extend the rPGA pipeline to identify per-
sonal specific splice junctions arising from other types of
genomic variants, such as indels or polymorphic structural
variations.
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